We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TRK

News List

Bayer’s Vitrakvi shows long-term efficacy in TRK fusion-positive cancers pharmatimes
September 21, 2020
Bayer’s tumour agnostic therapy Vitrakvi has demonstrated sustained, long-term efficacy and safety in a number of tropomyosin receptor kinase (TRK) fusion-positive cancers, including lung and thyroid tumours.
FDA approves first oral TRK inhibitor with Loxo Oncology's Vitrakvi pharmafile
November 28, 2018
The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), for the treatment of solid tumours
Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer endpts
November 27, 2018
The FDA has hustled up a quick OK for larotrectinib, offering their stamp of approval for a site-agnostic cancer drug from Loxo Oncology and their partners at Bayer...
Larotrectinib shows promise in paediatric patients with TRK gene mutations europeanpharmaceuticalreview
April 09, 2018
A new cancer drug has proven safe and effective for paediatric patients with a rare tumour gene mutation…